Developer docs
API playgroundTry for free, no card

Search company profiles

BioConnection

Full company profile

uuid003fpjc

Namestring
BioConnection
Legal namestring
BioConnection B.V.
Company typeenum
Private
Founded yearint
2005
Descriptiontext

BioConnection B.V. is a Netherlands-based Contract Development and Manufacturing Organization (CDMO) founded in 2005 and headquartered in Oss, with 101–250 employees. The company specializes in aseptic fill & finish services for sterile injectable drug products — including vials, syringes and cartridges — at both clinical and commercial scales, complemented by lyophilization (freeze-drying) capacity of up to 10 m² shelf area. The Oss production facility is dual-approved by the EMA and the US-FDA and operates four class A aseptic filling lines within a single site, enabling an unusually broad batch-size envelope from a single unit (hand fill, personalized medicine) up to 150,000 units per batch (automated commercial scale), with annual capacity certified in 2021 for up to 40 million liquid vials and 4 million freeze-dried vials.

BioConnection serves small-to-mid-sized biopharmaceutical and biotech companies that lack their own sterile manufacturing infrastructure, with named customers spanning respiratory therapeutics (Verona Pharma), oncology (BioLineRx, Lava Therapeutics, AIMM Therapeutics), vaccines (Nykode, AdaptVac), hematology (VarmX), and live biotherapeutic products (Infant Bacterial Therapeutics). The service offering extends beyond fill & finish to formulation and process development, analytical development and validation, container closure integrity and sterility testing, stability studies, secondary packaging with serialization, tech transfer, scale-up, and regulatory support, all coordinated by a dedicated Program Management team across the drug lifecycle.

Revenue is generated through project-based contract manufacturing fees priced per program, with costs varying by batch specifications, scale (clinical vs. commercial), fill volume, and service scope. Go-to-market is relationship-driven and direct: a Business Development team of four managers engages enterprise customers globally, supplemented by an active presence at major industry events (CPHI, BIO-Europe, BioProcess International, TIDES, World Orphan Drug Congress, among others). In April 2022 the company completed a capital raise led by Gimv with participation from Pharming Group, Mibiton and management, and in May 2024 entered a strategic partnership with AGC Biologics to offer integrated 'gene to vial' services; in March 2026 BioConnection ordered a new robotized isolator filling line and freeze-dryer expected operational in H2 2028.

Short descriptiontext

BioConnection is a Netherlands-based, EMA and US-FDA-approved CDMO providing aseptic fill & finish and lyophilization services for sterile injectable drug products, serving small-to-mid-sized biopharma companies across clinical and commercial scales from its Oss facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOss, Netherlands
HQ citystring
Oss
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
aseptic fill finish, lyophilization services, contract manufacturing organization, sterile injectable manufacturing, GMP biopharmaceutical manufacturing
Industry4 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services (Fill & Finish)
TypeProfessional Services
Description

BioConnection generates revenue through contract manufacturing fees for aseptic fill & finish services, including automated filling, lyophilization, and small-scale hand fill. Services are priced per project/program, with costs varying based on batch size, product complexity, scale (clinical vs. commercial), and project scope. Revenue is project-based and non-recurring per contract, though ongoing programs with existing clients generate repeat business.

bioconnection.eu
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details1 tier
1Project-based contract manufacturing — pricing varies by program scope and specifications
ModelOtherBilling cadenceMulti-year contract
Notes

Since every program is unique, the costs depend on the specifications of the required program. Business Development team provides preliminary pricing based on specific client requirements.

bioconnection.eu
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioConnection is a specialized Contract Development and Manufacturing Organization (CDMO) providing aseptic fill & finish services for sterile drug products into vials, syringes, and cartridges at EMA and US-FDA-approved GMP facilities in Oss, the Netherlands. Core offerings include automated and manual aseptic filling (batch sizes from 1 unit up to 150,000 units per batch), lyophilization/freeze-drying (shelf areas 3-10 m²), and integrated additional services including formulation development, analytical testing, secondary packaging with serialization, technology transfer, scale-up, and regulatory support for clinical and commercial supply worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Up to 40 million vials per year for liquid products and up to 4 million vials per year for freeze-dried products from the large-scale filling line
+1 more record
Product overview1 text field

BioConnection is a specialized CDMO (Contract Development and Manufacturing Organization) providing a comprehensive suite of sterile drug product manufacturing services. The core offering centers on Fill & Finish Services and Lyophilization Services for vials and syringes, supported by additional services including Development Services, Analytical Services, and Secondary Packaging. The company operates from an EMA and US-FDA-approved facility in Oss, Netherlands, and supports the entire drug lifecycle from toxicology studies through Phase I-III clinical manufacturing to commercial market production. The product portfolio is unified under a single service delivery model where all capabilities are coordinated through a dedicated program management team to ensure seamless project transitions.

Product and service7 records
1Fill & Finish Services
CategoryAseptic Fill & Finish
Description

Aseptic filling of sterile drug products into vials (2 RDIN to 50 RDIN) and prefilled syringes (0.5 ml to 10 ml) with batch sizes from 1 unit up to 150,000 units per batch, supporting both clinical and commercial scale manufacturing at EMA and US-FDA-approved GMP facilities for biopharmaceutical customers.

2Lyophilization (Freeze-Drying) Services
CategoryLyophilization
Description

Freeze-drying services with shelf areas ranging from 3 m² up to 10 m² across two filling lines, fully compliant with EMA and US-FDA regulations for lyophilized injectable products, supporting both clinical and commercial supply for biopharmaceutical clients.

3Development Services
CategoryDrug Product Development
Description

Formulation development for liquid and lyophilized injectables, process development for aseptic filling, and lyophilization cycle development to optimize product quality and stability for client drug products across clinical and commercial stages.

4Analytical Services
CategoryAnalytical Services
Description

Stability studies, container closure integrity testing (CCIT), method validation or transfer, sterility testing, bioburden determination, and bacterial endotoxin testing to support GMP manufacturing release and stability programs for client drug products.

5Secondary Packaging
CategorySecondary Packaging
Description

Labeling and packaging of vials and prefilled syringes for clinical and commercial use, with serialization services available to comply with country-specific regulatory requirements for global market supply.

6Hand Fill Services
CategoryAseptic Fill & Finish (Manual)
Description

Specialized small-scale manual aseptic fill production for personalized medicines, ATMP support, and early-stage clinical trials in class B to D cleanrooms with class A manual fill, handling batch sizes from 1 unit up to around 1,000 units, including BSL-2 ready capability.

7Technology Transfer, Scale-up and PPQ Services
CategoryManufacturing Support Services
Description

Technology transfer, scale-up, and Process Performance Qualification (PPQ) execution to support seamless progression of client drug products from development through clinical stages to commercial manufacturing, including regulatory support for marketing authorization submissions.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Infant Bacterial Therapeutics (IBT)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-11
Description

IBT partnered with BioConnection for Process Performance Qualification (PPQ) of Drug Product for IBT's lead Live Biotherapeutic Product IBP-9414, intended for premature infants. PPQ manufacturing is conducted at BioConnection's Oss facility. This represents a key step in IBT's path to commercial supply, with IBT noting BioConnection currently supplies pharmaceutical products to European and US markets.

ibtherapeutics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-22
Description

Strategic partnership announced May 2024 between AGC Biologics (a leading global CDMO) and BioConnection. The partnership provides end-to-end biopharmaceutical development and manufacturing capabilities combining AGC Biologics' drug substance expertise with BioConnection's specialized aseptic fill & finish services. Customers receive a seamless 'gene to vial' value chain service with a single contract and project management team, accelerating timelines and reducing complexity.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Rommelag is a leading aseptic fill-finish CDMO offering blow-fill-seal and vial filling services. Direct peer in sterile injectable manufacturing with comparable customer base.

2Millmount Healthcare (Uniphar)
TypeRegional player
Description

Millmount Healthcare, part of Uniphar, is an Irish CDMO providing sterile injectable fill-finish and lyophilization. Comparable capability profile, focused primarily on European market similar to BioConnection.

TypeDirect peer
Description

HALIX is a Dutch CDMO specializing in GMP manufacturing of vaccines and biopharmaceuticals, including aseptic fill-finish. Direct geographic and capability peer based in the Netherlands.

TypeBroad incumbent
Description

Lonza is a global CDMO leader offering biologics manufacturing and fill-finish services. Overlaps with BioConnection in sterile injectable fill-finish, but operates as a broad incumbent across modalities and scales.

5Recipharm
TypeDirect peer
Description

Recipharm is a European CDMO offering aseptic fill-finish and lyophilization services to biopharma customers. Directly comparable to BioConnection in fill-finish capabilities, geographic focus, and customer segments.

TypeBroad incumbent
Description

Catalent is one of the largest global CDMOs with extensive aseptic fill-finish capacity across multiple modalities. Serves similar biotech customers but at materially greater scale and broader geographic footprint.

TypeDirect peer
Description

Vibalogics is a specialized CDMO focused on viral vaccines and gene therapies with aseptic fill-finish capabilities. Direct peer in serving biotechs with complex sterile injectable modalities.

TypeDirect peer
Description

AGC Biologics is a global CDMO with microbial and mammalian biologics manufacturing that recently partnered with BioConnection to provide integrated 'gene to vial' services. They are direct peers in CDMO services with a complementary (rather than overlapping) scope.

TypeBroad incumbent
Description

Eurofins CDMO (formerly Alpharma) provides contract development and manufacturing services including sterile fill-finish. Broad incumbent with overlapping capabilities and similar European presence.

TypeDirect peer
Description

SK biotek is an Asia-based CDMO with strong fill-finish capabilities serving global pharma and biotech. Comparable in scale and service mix, with a similar focus on small-to-mid biopharma customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioConnection

Biopharmaceutical CDMO Servicesbioconnection.eu

BioConnection is a Netherlands-based, EMA and US-FDA-approved CDMO providing aseptic fill & finish and lyophilization services for sterile injectable drug products, serving small-to-mid-sized biopharma companies across clinical and commercial scales from its Oss facility.

What BioConnection does

BioConnection B.V. is a Netherlands-based Contract Development and Manufacturing Organization (CDMO) founded in 2005 and headquartered in Oss, with 101–250 employees. The company specializes in aseptic fill & finish services for sterile injectable drug products — including vials, syringes and cartridges — at both clinical and commercial scales, complemented by lyophilization (freeze-drying) capacity of up to 10 m² shelf area. The Oss production facility is dual-approved by the EMA and the US-FDA and operates four class A aseptic filling lines within a single site, enabling an unusually broad batch-size envelope from a single unit (hand fill, personalized medicine) up to 150,000 units per batch (automated commercial scale), with annual capacity certified in 2021 for up to 40 million liquid vials and 4 million freeze-dried vials.

BioConnection serves small-to-mid-sized biopharmaceutical and biotech companies that lack their own sterile manufacturing infrastructure, with named customers spanning respiratory therapeutics (Verona Pharma), oncology (BioLineRx, Lava Therapeutics, AIMM Therapeutics), vaccines (Nykode, AdaptVac), hematology (VarmX), and live biotherapeutic products (Infant Bacterial Therapeutics). The service offering extends beyond fill & finish to formulation and process development, analytical development and validation, container closure integrity and sterility testing, stability studies, secondary packaging with serialization, tech transfer, scale-up, and regulatory support, all coordinated by a dedicated Program Management team across the drug lifecycle.

Revenue is generated through project-based contract manufacturing fees priced per program, with costs varying by batch specifications, scale (clinical vs. commercial), fill volume, and service scope. Go-to-market is relationship-driven and direct: a Business Development team of four managers engages enterprise customers globally, supplemented by an active presence at major industry events (CPHI, BIO-Europe, BioProcess International, TIDES, World Orphan Drug Congress, among others). In April 2022 the company completed a capital raise led by Gimv with participation from Pharming Group, Mibiton and management, and in May 2024 entered a strategic partnership with AGC Biologics to offer integrated 'gene to vial' services; in March 2026 BioConnection ordered a new robotized isolator filling line and freeze-dryer expected operational in H2 2028.

BioConnection firmographics

Firmographics
Name
BioConnection
Legal name
BioConnection B.V.
Website
https://bioconnection.eu
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
BioConnection is a Netherlands-based, EMA and US-FDA-approved CDMO providing aseptic fill & finish and lyophilization services for sterile injectable drug products, serving small-to-mid-sized biopharma companies across clinical and commercial scales from its Oss facility.
Ownership category
akta.pro rank

BioConnection industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Aseptic fill finish
  • Lyophilization services
  • Contract manufacturing organization
  • Sterile injectable manufacturing
  • GMP biopharmaceutical manufacturing

Where BioConnection is headquartered

Location

Headquarters

HQ city
Oss
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

BioConnection business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services (Fill & Finish): BioConnection generates revenue through contract manufacturing fees for aseptic fill & finish services, including automated filling, lyophilization, and small-scale hand fill. Services are priced per project/program, with costs varying based on batch size, product complexity, scale (clinical vs. commercial), and project scope. Revenue is project-based and non-recurring per contract, though ongoing programs with existing clients generate repeat business.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based contract manufacturing — pricing varies by program scope and specifications

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

BioConnection product offering

Product offering

Core offering

BioConnection is a specialized Contract Development and Manufacturing Organization (CDMO) providing aseptic fill & finish services for sterile drug products into vials, syringes, and cartridges at EMA and US-FDA-approved GMP facilities in Oss, the Netherlands. Core offerings include automated and manual aseptic filling (batch sizes from 1 unit up to 150,000 units per batch), lyophilization/freeze-drying (shelf areas 3-10 m²), and integrated additional services including formulation development, analytical testing, secondary packaging with serialization, technology transfer, scale-up, and regulatory support for clinical and commercial supply worldwide.

Product overview

BioConnection is a specialized CDMO (Contract Development and Manufacturing Organization) providing a comprehensive suite of sterile drug product manufacturing services. The core offering centers on Fill & Finish Services and Lyophilization Services for vials and syringes, supported by additional services including Development Services, Analytical Services, and Secondary Packaging. The company operates from an EMA and US-FDA-approved facility in Oss, Netherlands, and supports the entire drug lifecycle from toxicology studies through Phase I-III clinical manufacturing to commercial market production. The product portfolio is unified under a single service delivery model where all capabilities are coordinated through a dedicated program management team to ensure seamless project transitions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Fill & Finish Services Aseptic filling of sterile drug products into vials (2 RDIN to 50 RDIN) and prefilled syringes (0.5 ml to 10 ml) with batch sizes from 1 unit up to 150,000 units per batch, supporting both clinical and commercial scale manufacturing at EMA and US-FDA-approved GMP facilities for biopharmaceutical customers.
  • Lyophilization (Freeze-Drying) Services Freeze-drying services with shelf areas ranging from 3 m² up to 10 m² across two filling lines, fully compliant with EMA and US-FDA regulations for lyophilized injectable products, supporting both clinical and commercial supply for biopharmaceutical clients.
  • Development Services Formulation development for liquid and lyophilized injectables, process development for aseptic filling, and lyophilization cycle development to optimize product quality and stability for client drug products across clinical and commercial stages.
  • Analytical Services Stability studies, container closure integrity testing (CCIT), method validation or transfer, sterility testing, bioburden determination, and bacterial endotoxin testing to support GMP manufacturing release and stability programs for client drug products.
  • Secondary Packaging Labeling and packaging of vials and prefilled syringes for clinical and commercial use, with serialization services available to comply with country-specific regulatory requirements for global market supply.
  • Hand Fill Services Specialized small-scale manual aseptic fill production for personalized medicines, ATMP support, and early-stage clinical trials in class B to D cleanrooms with class A manual fill, handling batch sizes from 1 unit up to around 1,000 units, including BSL-2 ready capability.
  • Technology Transfer, Scale-up and PPQ Services Technology transfer, scale-up, and Process Performance Qualification (PPQ) execution to support seamless progression of client drug products from development through clinical stages to commercial manufacturing, including regulatory support for marketing authorization submissions.

Quantifiable outcome

  • Up to 40 million vials per year for liquid products and up to 4 million vials per year for freeze-dried products from the large-scale filling line
  • +1 more outcomes

Companies that use BioConnection

Customer profile

Named customers9 records

Segments3 records

Ideal customer profiles2 records

BioConnection technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

BioConnection partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Infant Bacterial Therapeutics (IBT)coreStrategic or Co-development Partner · 11 December 2025IBT partnered with BioConnection for Process Performance Qualification (PPQ) of Drug Product for IBT's lead Live Biotherapeutic Product IBP-9414, intended for premature infants. PPQ manufacturing is conducted at BioConnection's Oss facility. This represents a key step in IBT's path to commercial supply, with IBT noting BioConnection currently supplies pharmaceutical products to European and US markets.
  • AGC BiologicscoreStrategic or Co-development Partner · 22 May 2024Strategic partnership announced May 2024 between AGC Biologics (a leading global CDMO) and BioConnection. The partnership provides end-to-end biopharmaceutical development and manufacturing capabilities combining AGC Biologics' drug substance expertise with BioConnection's specialized aseptic fill & finish services. Customers receive a seamless 'gene to vial' value chain service with a single contract and project management team, accelerating timelines and reducing complexity.

Scale indicators6 records

Recent moves10 records

Expansion highlights5 records

BioConnection competitors and assessment

Company assessment

Direct peers

  • Rommelag (Holopack): Rommelag is a leading aseptic fill-finish CDMO offering blow-fill-seal and vial filling services. Direct peer in sterile injectable manufacturing with comparable customer base.
  • HALIX: HALIX is a Dutch CDMO specializing in GMP manufacturing of vaccines and biopharmaceuticals, including aseptic fill-finish. Direct geographic and capability peer based in the Netherlands.
  • Recipharm: Recipharm is a European CDMO offering aseptic fill-finish and lyophilization services to biopharma customers. Directly comparable to BioConnection in fill-finish capabilities, geographic focus, and customer segments.
  • Vibalogics: Vibalogics is a specialized CDMO focused on viral vaccines and gene therapies with aseptic fill-finish capabilities. Direct peer in serving biotechs with complex sterile injectable modalities.
  • AGC Biologics: AGC Biologics is a global CDMO with microbial and mammalian biologics manufacturing that recently partnered with BioConnection to provide integrated 'gene to vial' services. They are direct peers in CDMO services with a complementary (rather than overlapping) scope.
  • SK biotek: SK biotek is an Asia-based CDMO with strong fill-finish capabilities serving global pharma and biotech. Comparable in scale and service mix, with a similar focus on small-to-mid biopharma customers.

Regional players

  • Millmount Healthcare (Uniphar): Millmount Healthcare, part of Uniphar, is an Irish CDMO providing sterile injectable fill-finish and lyophilization. Comparable capability profile, focused primarily on European market similar to BioConnection.

Broad incumbents

  • Lonza: Lonza is a global CDMO leader offering biologics manufacturing and fill-finish services. Overlaps with BioConnection in sterile injectable fill-finish, but operates as a broad incumbent across modalities and scales.
  • Catalent: Catalent is one of the largest global CDMOs with extensive aseptic fill-finish capacity across multiple modalities. Serves similar biotech customers but at materially greater scale and broader geographic footprint.
  • Eurofins CDMO: Eurofins CDMO (formerly Alpharma) provides contract development and manufacturing services including sterile fill-finish. Broad incumbent with overlapping capabilities and similar European presence.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks4 records

Key highlights6 records

Customer concentration

BioConnection social profiles

Digital presence

BioConnection compliance and trust

Trust signal

Compliance6 records

BioConnection financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioConnection leadership team

Management profile

Number of profiles

Profiles10 records

BioConnection funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioConnection M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioConnection

What does BioConnection do?

BioConnection is a specialized Contract Development and Manufacturing Organization (CDMO) providing aseptic fill & finish services for sterile drug products into vials, syringes, and cartridges at EMA and US-FDA-approved GMP facilities in Oss, the Netherlands. Core offerings include automated and manual aseptic filling (batch sizes from 1 unit up to 150,000 units per batch), lyophilization/freeze-drying (shelf areas 3-10 m²), and integrated additional services including formulation development, analytical testing, secondary packaging with serialization, technology transfer, scale-up, and regulatory support for clinical and commercial supply worldwide.

Is BioConnection a public or private company?

BioConnection is a private company. It is classified as venture growth investor backed and is currently operating.

When was BioConnection founded?

BioConnection was founded in 2005. It employs 51 to 100 people.

Where is BioConnection based?

BioConnection is headquartered in Oss, Netherlands, in the Europe region.

How does BioConnection make money?

One revenue line is on record: contract Manufacturing Services (Fill & Finish).

Who are BioConnection's main competitors?

Direct peers on record are Rommelag (Holopack), HALIX, Recipharm, Vibalogics, AGC Biologics and SK biotek. Millmount Healthcare (Uniphar) is listed as a regional player. Broad incumbents are Lonza, Catalent and Eurofins CDMO.

Does BioConnection have an API?

No public API is recorded for BioConnection.

What industry is BioConnection in?

BioConnection's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireBiopharmaceutical CMO Market Analysis Report 2026: $54.54 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe biopharmaceutical CMO market is projected to grow from $28.02 billion in 2025 to $32.03 billion in 2026, a 14.3% CAGR, and reach $54.54 billion by 2030. Growth is driven by biologics pipeline development, biosimilar approvals, and demand for flexible manufacturing. North America led in 2025, with Asia-Pacific expected to see the fastest growth.IbtherapeuticsInfant Bacterial Therapeutics secures partnership with BioConnection for production of Drug ProductInfant Bacterial Therapeutics AB has partnered with BioConnection, a pharmaceutical contract manufacturing organization, to initiate Process Performance Qualification for the Drug Product of its lead Live Biotherapeutic Product, IBP-9414. The PPQ program will be conducted at BioConnection's manufacturing facility in Oss, the Netherlands. IBT's mission is to develop and commercialize pharmaceuticals for diseases affecting premature babies.GlobeNewswireBioConnection appoints Richard Sewalt as New Chief Commercial OfficerBioConnection appointed Richard Sewalt as Chief Commercial Officer on 6 September 2024. He brings over 20 years of biopharmaceutical commercial experience, including recent CCO roles at Synthon and Galenicum. He aims to expand the business and create value for patients.GlobeNewswireBioConnection appoints Dr. Gary M. Phillips as new Chairman of its Supervisory BoardBioConnection appointed Dr. Gary M. Phillips as Chairman of its Supervisory Board, succeeding Rob Prins. Phillips brings over three decades of pharmaceutical industry experience, including roles at Anaveon, OrphoMed, and Mallinckrodt. He will lead the board upon his appointment.GlobeNewswireAGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing OfferingAGC Biologics and BioConnection announced a strategic partnership to offer end-to-end biopharmaceutical development and manufacturing, combining drug substance and aseptic filling services. The partnership aims to provide a single contract for developers, addressing potential impacts from the U.S. BIOSECURE Act. The companies will continue offering services independently.AgcbioAGC Biologics and BioConnection Partner to Offer Drug Product ServicesAGC Biologics and BioConnection announced a strategic partnership combining drug substance development and manufacturing with BioConnection's aseptic filling of vials and syringes, under a single contract and project management team. The joint offering spans Japan, the U.S. and Europe and targets developers potentially affected by the proposed U.S. BIOSECURE Act. Both companies continue to offer services independently.PR NewswireDutch CDMO BioConnection announces substantial investment by Gimv, supported by existing shareholdersBioConnection, a Dutch CDMO, completed a capital raise led by Gimv with support from existing shareholders. The funds will accelerate growth, strengthen infrastructure, and expand production capacity, including a new line certified for up to 40 million vials annually.BioconnectionDutch CDMO BioConnection announces substantial investment by Gimv, supported by existing shareholdersBioConnection, a Dutch CDMO based in Oss, announced a substantial investment led by the European investment company Gimv, aiming to enhance its services for biopharmaceutical companies. The funding will support the acceleration of growth and quality control, facilitating the company’s capabilities in developing targeted therapies. This investment positions BioConnection to meet the evolving demands of the pharmaceutical industry and enhance its production capacity and infrastructure.biopharma-reporter.comCDMO deals roundup: AGC Biologics, Halix and BioConnection support monoclonal antibody, gene therapy and vaccine projectsAGC Biologics partnered with 4Teen4 to develop and manufacture Procizumab, a monoclonal antibody for cardiovascular failure, with production in Japan and Denmark. Halix will produce gene therapy trial material for Amarna's AMA005, while BioConnection will manufacture vaccine candidates for Nykode. BioConnection also expanded its Copenhagen capacity and received GMP certification for a new filling line.PR NewswireBioConnection to manufacture clinical trial material for Nykode Therapeutics' vaccineBioConnection, a Dutch contract development and manufacturing organization (CDMO), announced that Nykode Therapeutics AS has selected it for the aseptic manufacturing of Nykode's lead vaccine candidate for clinical trials. The partnership leverages BioConnection's EMA and FDA-certified facilities and capabilities for small-scale manual fill-and-finish operations suited to Phase I trial requirements. Nykode Therapeutics, a clinical-stage biotechnology company focused on cancer and infectious disease vaccines, chose BioConnection for its tailored production solutions and regulatory track record.